wla(warner lambert) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sonki who wrote (544)	2/19/1999 1:58:00 PM
From: Anthony Wong	Read Replies (2) of 942

Sonki, I agree with Judy. I've been through a similar situation with LLY last year - LLY dropped to $59 on disappointing Evista scripts, as if Evista is LLY's only drug. Look where it is now and there are 2 buys on LLY yesterday. Fundamentally speaking, even without Rezulin (worse case scenario), WLA is still growing at 25% or more per year. The stock would rebound after the FDA meeting. I don't expect them to take the drug off the market. Lipitor is still gaining market share and the market for cholesterol-lowering drugs is expanding (aging baby-boomers). WLA has yet to choose a drug in PFE's pipeline to co-market, and I don't expect them to choose anything less than a blockbuster drug. Anthony

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next